/

Sociétés

As

Non vérifié

AstraZeneca

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueMédecine - DiversSanté

113 communiqués de presse

Voir tous les communiqués de presse

12/06/2026

Hygiène alimentaire

Troisième âge

Médecine - Divers

Biotechnologie

Santé

Vitrines/Shopping

Industrie pharmaceutique

Oncologie

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

Source

Émetteur

1.00

0

02/06/2026

Oncologie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Industrie

Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial

Source

Émetteur

1.00

0

01/06/2026

Science

Médecine - Divers

Biotechnologie

Santé

Industrie pharmaceutique

Santé Publique

Oncologie

Événements

Industrie

IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial

Source

Émetteur

1.00

0

29/05/2026

Oncologie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Industrie

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

Source

Émetteur

1.00

0

22/05/2026

Industrie

Science

Médecine - Divers

Hygiène alimentaire

Biotechnologie

Santé

Industrie pharmaceutique

Oncologie

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates

Source

Émetteur

1.00

0

22/05/2026

Science

Médecine - Divers

Biotechnologie

Santé

Industrie pharmaceutique

Santé Publique

Oncologie

Événements

Industrie

AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026

Source

Émetteur

1.00

0

18/05/2026

BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

Source

Émetteur

1.00

0

16/05/2026

Industrie

Science

Médecine - Divers

Hygiène alimentaire

Biotechnologie

Santé

Industrie pharmaceutique

Oncologie

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer

Source

Émetteur

1.00

0

14/05/2026

Industrie

Oncologie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial

Source

Émetteur

1.00

0

01/05/2026

Industrie

Science

Biotechnologie

Industrie pharmaceutique

Oncologie

Santé

Hygiène alimentaire

Médecine - Divers

TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0